Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

Slides:

Advertisements

Similar presentations

Haakon Ragde M.D. The Haakon Ragde Foundation. B Cell The Star Players Most potent cells of the immune system T Cell Dendritic Cell Antibodies.

Advertisements

Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.

Meredith Baker, MD PI: Bo Lu, MD – Radiation Oncology May 29th, 2014

Rapporteur Report – Track A Basic and Translational Sciences

Results of Definitive Radiotherapy in Anal Canal Carcinoma

J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Immunotherapy of hepatocellular carcinoma

Staging Cancer.

Advances in Specific Immunotherapy for Prostate Cancer

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients by Raffaella.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Immunologic responses after the MN-mediated cancer immunotherapy.

Course of disease and immune responses seen in patient LAU 672.

Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Figure 2 Logistical requirements for autologous

Clinical responses in patients.

Pten deficiency induces strong stromal reaction with immune cell infiltration and promotes the development of invasive and metastatic pancreatic tumors.

Immunotherapy for Lung Cancer

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

Quantification of MHC-I, β2m, and T-cell subsets.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

IL6 mRNA is not detected in metastatic prostate cancer cells.

Antigen-specific CD8+ T cells express higher levels of PD-1 in animals that received the optimized SSX2 vaccine. Antigen-specific CD8+ T cells express.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

AXL is not expressed in human prostate tumors.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.

Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.

Coexpression of other immune genes with ImSig core signatures.

CD4+ cells are required to generate protective immunity against the MT-HA tumor in HA104 mice. CD4+ cells are required to generate protective immunity.

Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. Ex vivo imaging of lymph nodes with tumor metastasis using.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Lesions and healthy organs dosimetry.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

Antigen expression and Breslow thickness.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional.

Progression and survival analysis.

Serial CT scan images from patient with a partial response.

Detection of E-cadherin fragments in human prostate cancer metastases.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Vorozole treatment-associated changes in protein abundance of multiple antigens. Vorozole treatment-associated changes in protein abundance of multiple.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Induction of NY-ESO-1-specific CD4+ and CD8+ T cell responses after in vitro presensitization with NY-ESO-1 p or Ad2/ESO. Induction of NY-ESO-1-specific.

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Presentation transcript:

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced immune responses. A, the course of disease is shown above the timeline. Before radiotherapy and immunotherapy with TL-DC, the tumor rapidly progressed to regional lymph nodes (LN) and to the brain. After radiotherapy for brain metastases, the patient showed a prolonged time to progression of 16 months. Since December 2003, the patient has remained free of disease. Immunotherapeutic treatments are shown below the timeline. M3, MAGE-A3 peptide vaccination. Continuous vaccination with TL-DC correlated with long-term tumor control. B, antibody (Ab) responses against the cancer–testis antigens NY-ESO-1, MAGE-A1, and MAGE-A3. The patient developed NY-ESO-1 antibodies in November 2002 after gamma-knife radiation of brain metastasis. After surgical removal of mesenteric lymph node metastasis in December 2003, NY-ESO-1 antibody decreased and has not been detectable at all since July 2004. Antibody responses to MAGE-A1 and MAGE-A3 were not observed at any time. C, ex vivo tetramer analysis showing strong expansion of MAGE-A1p161–169–specific CD8+ T cells after radiotherapy and immunotherapy with TL-DC in 2004 that persisted throughout the course of immunotherapy and is still detectable ex vivo in the patient's peripheral blood without any evidence of detectable disease. Julia Karbach et al. Cancer Immunol Res 2014;2:404-409 ©2014 by American Association for Cancer Research